The clinical stage development company, located in Cambridge, Massachusetts, focuses on immune modulatory drugs for diseases such as ALS and Alzheimer's. Anelixis Therapeutics is dedicated to advancing treatments that will help patients fight their disease progression, with a portfolio centered around these diseases. The company operates as a facilitator of pre-clinical drug development, with their most notable project being a novel anti CD40L antibody.